Semin Thromb Hemost 2002; 28(1): 29-38
DOI: 10.1055/s-2002-20562
Copyright © 2002 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA. Tel.: +1(212) 584-4662

Effect of Antihemostatic Agents on Experimental Tumor Dissemination

John L. Francis, Ali Amirkhosravi
  • Clinical and Research Laboratories, Florida Hospital Cancer Institute, Orlando, Florida
Further Information

Publication History

Publication Date:
05 March 2002 (online)

ABSTRACT

There is now considerable evidence that the blood coagulation system plays an important role in the biology of malignant tumors. This evidence has been derived from a combination of clinical, biochemical, histological, and pharmacological observations that point to the possibility of favorably affecting the course of malignant disease with agents that interfere with blood coagulation pathways. For a number of years our laboratory has used experimental models of blood-borne metastasis to study the events that follow the introduction of procoagulant-bearing tumor cells into the circulating blood. This article summarizes our experience with these models, which suggests that intravascular coagulation is a necessary prelude to lung tumor formation and that interruption of coagulation pathways in various ways may be an effective antimetastatic strategy. We have shown that anticoagulation with commonly used agents such as unfractionated heparin and warfarin (Coumadin) prevent tumor formation by limiting the ability of tumor cells to be retained in the pulmonary microvasculature. Binding of fibrin-coated tumor cells to activated platelets is essential for this retention and, therefore, treatment with potent antiplatelet agents such as abciximab is also effective. The predominant tumor procoagulant is tissue factor (TF), and direct targeting of this protein with concanavalin A, monoclonal antibodies, and tissue factor pathway inhibitor (TFPI) has provided compelling evidence that TF is an important determinant of tumor seeding in these experimental models. Collectively, our data provide strong support for the concept that some form of anticoagulant therapy would be a useful adjunct to existing cancer treatments.

REFERENCES

  • 1 Hillen H F. Thrombosis in cancer patients.  Ann Oncol . 2000;  11(Suppl 3) 273-276
  • 2 Bick R L. Coagulation abnormalities in malignancy: a review.  Semin Thromb Hemost . 1992;  18 353-372
  • 3 Prandoni P, Lensing A WA, Büller H R. Deep-vein thrombosis and the incidence of subsequent symptomatic cancer.  N Engl J Med . 1992;  327 1128-1133
  • 4 Levine M. Treatment of thrombotic disorders in cancer patients.  Haemostasis . 1997;  27 38-43
  • 5 Kakkar A K, Williamson R C. Thromboprophylaxis in the cancer patient.  Haemostasis . 1998;  28(Suppl 3) 61-65
  • 6 Sun N CJ, McAfee W M, Hum G J, Weiner J M. Hemostatic abnormalities in malignancy, a prospective study of one hundred eight patients. Part 1. Coagulation studies.  Am J Clin Pathol . 1979;  71 10-16
  • 7 Francis J L, Francis D A, Gunathilagan G J. Assessment of hypercoagulability in patients with cancer using the Sonoclot analyzer and thromboelastography.  Thromb Res . 1994;  74 335-346
  • 8 Rickles F R, Edwards R L, Barb C, Cronlund M. Abnormalities of blood coagulation in patients with cancer. Fibrinopeptide A generation and tumor growth.  Cancer . 1983;  51 301-307
  • 9 Seitz R, Rappe N, Kraus M. Activation of coagulation and fibrinolysis in patients with lung cancer-relation to tumour stage and prognosis.  Blood Coagul Fibrinolysis . 1993;  4 249-254
  • 10 Duncan A, Howard T, League A. Markers of coagulation and hemostasis activation (MOCHA) as indicators of unsuspected malignancy.  Thromb Haemost . 1997;  85(Suppl) 123-123 Abst
  • 11 Brown J M. A study of the mechanism by which anticoagulation with warfarin inhibits blood-borne metastases.  Cancer Res . 1973;  33 1217-1224
  • 12 Poggi A, Mussoni L, Kornblihtt L. Warfarin enantiomers, anticoagulation and experimental tumour metastasis.  Lancet . 1978;  1 163-164
  • 13 Donati M B, Roncaglioni M C, Falanga A, Casali B, Semeraro N. Vitamin K-dependent procoagulant in cancer cells: a potential target for the anti-metastatic effect of warfarin.  Haemostasis . 1986;  16 288-294
  • 14 Goeting N LM, Trotter G A, Taylor I. Effect of warfarin on formation and growth of pre-neoplastic lesions in chemically-induced colorectal cancer in the rat.  Br J Surg . 1986;  73 487-489
  • 15 McCulloch P, George W D. Warfarin inhibition of metastasis: the role of anticoagulation.  Br J Surg . 1987;  74 879-883
  • 16 McCulloch P, George W D. Warfarin inhibits metastasis of Mtln3 rat mammary carcinoma without affecting primary tumour growth.  Br J Cancer . 1989;  59 179-183
  • 17 Thornes R D. Fibrin and cancer.  Br Med J . 1972;  1 110-111
  • 18 Zacharski L R. Small cell carcinoma of the lung: interaction with the blood coagulation mechanism and treatment with anticoagulants.  Onkologie . 1987;  10 264-270
  • 19 Daly L. The first international urokinase/warfarin trial in colorectal cancer.  Clin Exp Metastasis . 1991;  9 3-11
  • 20 Carpi A, Sagripanti A, Poddighe R, Gherarducci G, Nicolini A. Cancer incidence and mortality in patients with heart disease. Effect of oral anticoagulant therapy.  Am J Clin Oncol . 1995;  18 15-18
  • 21 Schulman S, Lindmarker P. Incidence of cancer after prophylaxis with warfarin against recurrent venous thromboembolism. Duration of Anticoagulation Trial.  N Engl J Med . 2000;  342 1953-1958
  • 22 Kakkar A K, Williamson R C. Prevention of venous thromboembolism in cancer using low-molecular-weight heparins.  Haemostasis . 1997;  27(Suppl 1) 32-37
  • 23 Ornstein D L, Zacharski L R. The use of heparin for treating human malignancies.  Haemostasis . 1999;  29(Suppl S1) 48-60
  • 24 Von Tempelhoff F G, Harenberg J, Niemann F. Effect of low molecular weight heparin (Certoparin) versus unfractionated heparin on cancer survival following breast and pelvic cancer surgery: a prospective randomized double-blind trial.  Int J Oncol . 2000;  16 815-824
  • 25 Engelberg H. Actions of heparin that may affect the malignant process.  Cancer . 1999;  85 257-272
  • 26 Zacharski L R, Memoli V A, Costantini V, Wojtukiewicz M Z, Ornstein D L. Clotting factors in tumour tissue: implications for cancer therapy.  Blood Coagul Fibrinolysis . 1990;  1 71-78
  • 27 Carmeliet P, Collen D. Molecular analysis of blood vessel formation and disease.  Am J Physiol . 1997;  273 H2091-H2104
  • 28 O'Brien D P. The molecular biology and biochemistry of tissue factor.  Baillieres Clin Haematol . 1989;  2 801-820
  • 29 Petersen L C, Freskgard P, Ezban M. Tissue factor-dependent factor VIIa signaling.  Trends Cardiovasc Med . 2000;  10 47-52
  • 30 Carmeliet P, Mackman N, Moons L. Role of tissue factor in embryonic blood vessel development.  Nature . 1996;  383 73-75
  • 31 Zhang Y, Deng Y, Luther T. Tissue factor controls the balance of angiogenic and antiangiogenic properties of tumor cells in mice.  J Clin Invest . 1994;  94 1320-1327
  • 32 Connolly D T. Vascular permeability factor: a unique regulator of blood vessel function.  J Cell Biochem . 1991;  47 219-223
  • 33 Shoji M, Abe K, Dillehay D. Tissue factor (TF) regulates the expression of vascular endothelial growth factor (VEGF) in vitro and angiogenesis in vivo in human breast cancer and melanoma.  Blood . 1996;  88 514a-514a Abst
  • 34 Carmeliet P, Moons L, Dewerchin M. Insights in vessel development and vascular disorders using targeted inactivation and transfer of vascular endothelial growth factor, the tissue factor receptor, and the plasminogen system.  Ann NY Acad Sci . 1997;  811 191-206
  • 35 Koomägi R, Volm M. Tissue-factor expression in human non-small-cell lung carcinoma measured by immunohistochemistry: correlation between tissue factor and angiogenesis.  Int J Cancer . 1998;  79 19-22
  • 36 Nakagawa K, Zhang Y, Tsuji H. The angiogenic effect of tissue factor on tumors and wounds.  Semin Thromb Hemost . 1998;  24 207-210
  • 37 Ollivier V, Bentolila S, Chabbat J, Hakim J, de Prost D. Tissue factor-dependent vascular endothelial growth factor production by human fibroblasts in response to activated factor VII.  Blood . 1998;  91 2698-2703
  • 38 Shoji M, Hancock W W, Abe K. Activation of coagulation and angiogenesis in cancer: immunohistochemical localization in situ of clotting proteins and vascular endothelial growth factor in human cancer.  Am J Pathol . 1998;  152 399-411
  • 39 Zucker S, Mirza H, Conner C E. Vascular endothelial growth factor induces tissue factor and matrix metalloproteinase production in endothelial cells: conversion of prothrombin to thrombin results in progelatinase A activation and cell proliferation.  Int J Cancer . 1998;  75 780-786
  • 40 Mechtcheriakova D, Wlachos A, Holzmüller H, Binder B R, Hofer E. Vascular endothelial cell growth factor-induced tissue factor expression in endothelial cells is mediated by EGR-1.  Blood . 1999;  93 3811-3823
  • 41 Rickles F R, Shoji M, Abe K. The role of the hemostatic system in tumor growth, metastasis, and angiogenesis: tissue factor is a bifunctional molecule capable of inducing both fibrin deposition and angiogenesis in cancer.  Int J Hematol . 2001;  73 145-150
  • 42 Shweioki D, Itin A, Soffer D, Keshet E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis.  Nature . 1992;  359 843-845
  • 43 Amirkhosravi A, Meyer T, Warnes G. Pentoxifylline inhibits hypoxia-induced upregulation of tumor cell tissue factor and vascular endothelial growth factor.  Thromb Haemost . 1998;  80 598-602
  • 44 Greeno E W, Bach R R, Moldow C F. Apoptosis is associated with increased cell surface tissue factor procoagulant activity.  Lab Invest . 1996;  75 281-289
  • 45 Dover R, Goeting N L, Taylor I, Roath O S, Francis J L. Factor X-activating activity in patients with colorectal carcinoma.  Br J Surg . 1987;  74 1122-1124
  • 46 Rickles F R, Hancock W W, Edwards R L, Zacharski L R. Antimetastatic agents. I. Role of cellular procoagulants in the pathogenesis of fibrin deposition in cancer and the use of anticoagulants and/or antiplatelet drugs in cancer treatment.  Semin Thromb Hemost . 1988;  14 88-94
  • 47 Amirkhosravi M, Francis J L. Procoagulant effects of the MC28 fibrosarcoma cell line in vitro and in vivo.  Br J Haematol . 1993;  85 736-744
  • 48 Edwards R L, Silver J, Rickles F R. Human tumor procoagulants: Registry of the Subcommittee of Haemostasis of the Scientific and Standardization Committee, International Society on Thrombosis and Haemostasis.  Thromb Haemost . 1993;  69 205-213
  • 49 Adamson A S, Luckert P, Pollard M. Procoagulant activity may be a marker of the malignant phenotype in experimental prostate cancer.  Br J Cancer . 1994;  69 286-290
  • 50 Amirkhosravi M, Francis J L. Coagulation activation by MC28 fibrosarcoma cells facilitates lung tumor formation.  Thromb Haemost . 1995;  73 59-65
  • 51 Francis J L, Carty N, Amirkhosravi M. The effect of warfarin and factor VII on tissue procoagulant activity and pulmonary seeding.  Br J Cancer . 1992;  65 329-334
  • 52 Chew E-C, Wallace A C. Demonstration of fibrin in early stages of experimental metastases.  Cancer Res . 1976;  36 1904-1909
  • 53 Crissman J D, Hatfield J, Shaldenbrand M, Sloane B F, Honn K V. Arrest and extravasation of B16 amelanotic melanoma in murine lungs: a light and electron microscope study.  Lab Invest . 1985;  53 470-478
  • 54 Biggerstaff J P, Seth N, Amirkhosravi A. Soluble fibrin augments platelet/tumor cell adherence in vitro and in vivo, and enhances experimental metastasis.  Clin Exp Metastasis . 1999;  17 723-730
  • 55 Borsig L, Wong R, Feramisco J. Heparin and cancer revisited: mechanistic connections involving platelets, P-selectin, carcinoma mucins, and tumor metastasis.  Proc Natl Acad Sci USA . 2001;  98 3352-3357
  • 56 Gasic G J, Gasic T B, Stewart C C. Antimetastatic effects associated with platelet reduction.  Proc Natl Acad Sci USA . 1968;  61 46-52
  • 57 Gasic G J, Gasic T B, Murphy S. Anti-metastatic effect of aspirin.  Lancet . 1972;  2 934
  • 58 Tzanakakis G N, Agarwal K C, Vezeridis M P. Prevention of human pancreatic cancer cell-induced hepatic metastasis in nude mice by dipyridamole and its analog RA-233.  Cancer . 1993;  71 2466-2471
  • 59 Amirkhosravi A, Amaya M, Siddiqui F A. Blockade of GpIIb/IIIa inhibits the release of vascular endothelial growth factor (VEGF) from tumor cell-activated platelets and experimental metastasis.  Platelets . 1999;  10 285-292
  • 60 Verheul H MW, Hoekman K, Luykx-de B S. Platelet: transporter of vascular endothelial growth factor.  Clin Cancer Res . 1997;  3 2187-2190
  • 61 Verheul H M, Pinedo H M. Tumor growth: a putative role for platelets?.  Oncologist . 1998;  3 II
  • 62 Wartiovaara U, Salven P, Mikkola H. Peripheral blood platelets express VEGF-C and VEGF which are released during platelet activation.  Thromb Haemost . 1998;  80 171-175
  • 63 Banks R E, Forbes M A, Kinsey S E. Release of the angiogenic cytokine vascular endothelial growth factor (VEGF) from platelets: significance for VEGF measurements and cancer biology.  Br J Cancer . 1998;  77 956-964
  • 64 Zacharski L R, Rosenstein R, Phillips P G. Concanavalin A inhibition of tissue factor (thromboplastin) activity.  Blood . 1974;  44 783-787
  • 65 Kirchhofer D, Banner D W. Molecular and structural advances in tissue factor-dependent coagulation.  Trends Cardiovasc Med . 1997;  7 316-324
  • 66 Broze Jr J G. Tissue factor pathway inhibitor and the revised theory of coagulation.  Annu Rev Med . 1995;  46 103-112
  • 67 Lindahl A K, Sandset P M, Abildgaard U. The present status of tissue factor pathway inhibitor.  Blood Coagul Fibrinolysis . 1992;  3 439-449
  • 68 Ostergaard P, Nordfang O, Petersen L C, Valentin S, Kristensen H. Is tissue factor pathway inhibitor involved in the antithrombotic effect of heparins-biochemical considerations.  Haemostasis . 1993;  23 107-111
  • 69 Lupu C, Poulsen E, Roquefeuil S. Cellular effects of heparin on the production and release of tissue factor pathway inhibitor in human endothelial cells in culture.  Arterioscler Thromb Vasc Biol . 1999;  19 2251-2262
  • 70 Werling R W, Zacharski L R, Kisiel W. Distribution of tissue factor pathway inhibitor in normal and malignant human tissues.  Thromb Haemost . 1993;  69 366-369
  • 71 Rapp J H, Pan X M, Ghermay A. A blinded trial of local recombinant tissue factor pathway inhibitor versus either local or systemic heparin in a vein bypass model.  J Vasc Surg . 1997;  25 726-729
  • 72 St Pierre J, Yang L Y, Tamirisa K. Tissue factor pathway inhibitor attenuates procoagulant activity and upregulation of tissue factor at the site of balloon-induced arterial injury in pigs.  Arterioscler Thromb Vasc Biol . 1999;  19 2263-2268
  • 73 Abraham E. Tissue factor inhibition and clinical trial results of tissue factor pathway inhibitor in sepsis.  Crit Care Med . 2000;  28 S31-S33
  • 74 Lincoff A M. First clinical investigation of a tissue-factor inhibitor administered during percutaneous coronary revascularization: a randomized, double-blinded, dose-escalation trial-Assessing safety and efficacy of FFR-FVIIa in percutaneous transluminal coronary angioplasty (ASIS) trial.  J Am Coll Cardiol . 2000;  136 312-313
  • 75 Nishida T, Ueno H, Atsuchi N. Adenovirus-mediated local expression of human tissue factor pathway inhibitor eliminates shear stress-induced recurrent thrombosis in the injured carotid artery of the rabbit.  Circ Res . 1999;  84 1446-1452
  • 76 Zoldhelyi P, Chen Z Q, Shelat H S, McNatt J M, Willerson J T. Local gene transfer of tissue factor pathway inhibitor regulates intimal hyperplasia in atherosclerotic arteries.  Proc Natl Acad Sci USA . 2001;  98 4078-4083
  • 77 Donnelly K M, Bromberg M E, Milstone A. Ancylostoma caninum anticoagulant peptide blocks metastasis in vivo and inhibits factor Xa binding to melanoma cells in vitro.  Thromb Haemost . 1998;  79 1041-1047
  • 78 Fischer E G, Ruf W, Mueller B M. Tissue factor-initiated thrombin generation activates the signaling thrombin receptor on malignant melanoma cells.  Cancer Res . 1995;  55 1629-1632
  • 79 Esumi N, Fan D, Fidler I J. Inhibition of murine melanoma experimental metastasis by recombinant desulfatohirudin, a highly specific thrombin inhibitor.  Cancer Res . 1991;  51 4549-4556
  • 80 Camerer E, Huang W, Coughlin S R. Tissue factor- and factor X-dependent activation of protease-activated receptor 2 by factor VIIa.  Proc Natl Acad Sci USA . 2000;  97 5255-5260
  • 81 Valentine K A, Hull R D, Pineo G F. Low-molecular-weight heparin therapy and mortality.  Semin Thromb Hemost . 1997;  23 173-178
  • 82 Zacharski L R, Ornstein D L, Mamourian A C. Low-molecular-weight heparin and cancer.  Semin Thromb Hemost . 2000;  26(Suppl 1) 69-77